ALPHALYTIK JOINS CERTANIA GROUP
The specialist in pharmaceutical analytical testing becomes part of the certania family.
Alphalytik Pharmaservice GmbH, a leading expert in pharmaceutical analytical testing, proudly announces its integration into CERTANIA, a dynamic group specializing in Testing, Inspection, and Certification services. This strategic move marks a significant milestone for Alphalytik, enhancing its capabilities to deliver specialized stability testing and method validation services to a broader range of pharmaceutical clients.
Founded in 1995 and headquartered in Berlin, Germany, Alphalytik has built a strong reputation as an independent laboratory specializing in GMP (Good Manufacturing Practice) and FDA (Food and Drug Administration) approved stability testing, method development, and release testing. With a focus on complex drug formulations, including low-dose and hormone preparations, Alphalytik serves a diverse clientele, including some of the world’s leading pharmaceutical companies. The company's expertise in ensuring the long-term safety and efficacy of pharmaceutical products has made it a trusted partner.
By joining CERTANIA, Alphalytik gains access to a powerful platform that will allow it to expand its service offerings and strengthen its position in the pharmaceutical market. This partnership will enable Alphalytik to address the growing demand for specialized pharmaceutical testing services, driven by increasing drug development and regulatory requirements.
Dr. Nicolas Schauer has been appointed as the new managing director and Dr. Richard Herzog, the founder of Alphalytik, will continue to support the company in a consulting role, ensuring a seamless transition and continuity in client relationships. "We are excited to join CERTANIA, a group that shares our commitment to excellence in pharmaceutical testing," said Dr. Richard Herzog, founder of Alphalytik. "This partnership will provide us with the resources and support needed to continue delivering high-quality, reliable services to our clients while also exploring new growth opportunities."
Karsten Xander, CEO and founder of CERTANIA, welcomed Alphalytik to the group, emphasizing the strategic importance of the acquisition. "The addition of Alphalytik significantly strengthens CERTANIA’s position in the pharmaceutical contract research and manufacturing segment. Their expertise in stability and release testing and method validation complements our existing services, and we see great potential for synergy and growth."
CERTANIA's acquisition of Alphalytik underscores the group’s commitment to expanding its capabilities in the life sciences sector, enhancing its market presence in Germany and beyond. The integration is expected to drive innovation, improve service offerings, and foster significant growth within the CERTANIA group.
CERTANIA provides a platform for mid-sized, knowledge-based companies to thrive under one umbrella, maintaining entrepreneurial freedom while benefiting from group resources and support.
